Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAA05 Injection in FLT3-positive Relapsed/Refractory AML
NCT05432401Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAA05 in acute myeloid leukemia (AML), sponsored by PersonGen BioTherapeutics. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose at 2 years. Status: unknown.
02
Drugs
TAA05
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05432401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432401.